JP2024526835A5 - - Google Patents

Info

Publication number
JP2024526835A5
JP2024526835A5 JP2024503351A JP2024503351A JP2024526835A5 JP 2024526835 A5 JP2024526835 A5 JP 2024526835A5 JP 2024503351 A JP2024503351 A JP 2024503351A JP 2024503351 A JP2024503351 A JP 2024503351A JP 2024526835 A5 JP2024526835 A5 JP 2024526835A5
Authority
JP
Japan
Prior art keywords
seq
nos
polypeptide
antigen
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073877 external-priority patent/WO2023004304A1/en
Publication of JP2024526835A publication Critical patent/JP2024526835A/ja
Publication of JP2024526835A5 publication Critical patent/JP2024526835A5/ja
Pending legal-status Critical Current

Links

JP2024503351A 2021-07-20 2022-07-19 Cd8結合ポリペプチド及びその使用 Pending JP2024526835A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163223786P 2021-07-20 2021-07-20
US63/223,786 2021-07-20
US202163288111P 2021-12-10 2021-12-10
US63/288,111 2021-12-10
PCT/US2022/073877 WO2023004304A1 (en) 2021-07-20 2022-07-19 Cd8-binding polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2024526835A JP2024526835A (ja) 2024-07-19
JP2024526835A5 true JP2024526835A5 (cg-RX-API-DMAC7.html) 2025-07-18

Family

ID=82898944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503351A Pending JP2024526835A (ja) 2021-07-20 2022-07-19 Cd8結合ポリペプチド及びその使用

Country Status (6)

Country Link
US (1) US20250320295A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373854A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024526835A (cg-RX-API-DMAC7.html)
CA (1) CA3225092A1 (cg-RX-API-DMAC7.html)
TW (1) TW202321283A (cg-RX-API-DMAC7.html)
WO (1) WO2023004304A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CN113924311A (zh) * 2019-01-07 2022-01-11 印希比股份有限公司 包含修饰的il-2多肽的多肽及其用途
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス, インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体
JP2022538139A (ja) * 2019-07-02 2022-08-31 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 変異体インターロイキン-2及び抗cd8抗体を含む免疫複合体
TW202519557A (zh) * 2019-09-04 2025-05-16 美商建南德克公司 Cd8 結合劑及其用途

Similar Documents

Publication Publication Date Title
JP2023513003A5 (cg-RX-API-DMAC7.html)
JP2020536549A5 (cg-RX-API-DMAC7.html)
JP2021520812A5 (cg-RX-API-DMAC7.html)
JP2020516287A5 (cg-RX-API-DMAC7.html)
JP2025504363A5 (cg-RX-API-DMAC7.html)
Blanco et al. Bispecific immunomodulatory antibodies for cancer immunotherapy
Nie et al. Biology drives the discovery of bispecific antibodies as innovative therapeutics
JP2021534783A5 (cg-RX-API-DMAC7.html)
US12384850B2 (en) Guidance and navigation control proteins and method of making and using thereof
JP2022116230A5 (cg-RX-API-DMAC7.html)
JP2025078629A5 (cg-RX-API-DMAC7.html)
JP2019513347A5 (cg-RX-API-DMAC7.html)
JP2021518142A5 (cg-RX-API-DMAC7.html)
JP2022516557A5 (cg-RX-API-DMAC7.html)
IL295878A (en) Methods for producing cells expressing a chimeric antigen receptor
IL319102A (en) Guidance and navigation control proteins and method for producing and using them
US20170073415A1 (en) Novel multispecific molecules and novel treatment methods based on such multispecific molecules
JP2013515509A5 (cg-RX-API-DMAC7.html)
JP2017513818A5 (cg-RX-API-DMAC7.html)
JP2017507917A (ja) 軟骨魚類由来の抗原認識ドメインを使用したキメラ抗原受容体
CN108250302A (zh) 一种多功能蛋白质
JP2024546999A5 (cg-RX-API-DMAC7.html)
JP2023534847A5 (cg-RX-API-DMAC7.html)
JP2024534471A5 (cg-RX-API-DMAC7.html)
JP2025503480A5 (cg-RX-API-DMAC7.html)